Opus Genetics (IRD) EBITDA Margin (2010 - 2026)
Opus Genetics (IRD) reported EBITDA Margin of 3038.25% for Q1 2026, down 285074.0% year-over-year from N/an in Q1 2025, and down 610.7% quarter-over-quarter from 427.5% in Q4 2025.
Opus Genetics (IRD) EBITDA Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 8 years of EBITDA Margin data on file, last reported at 3038.25% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 3038.25%, down 285074.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 892.36% (down 46295.0% YoY), and the FY2025 annual result was 349.33%, up 17407.0% from the prior year.
- EBITDA Margin slipped to 3038.25% in Q1 2026 per IRD's latest filing, from 427.5% in the prior quarter.
- Over five years, EBITDA Margin peaked at 85.17% in Q4 2022 and troughed at 3038.25% in Q1 2026.
- A 5-year average of 515.75% and a median of 307.33% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 44083 bps in 2025, then tumbled 285074 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 85.17% in 2022, then plunged by 433 bps to 283.56% in 2023, then plunged by 188 bps to 816.71% in 2024, then soared by 48 bps to 427.5% in 2025, then sank by 611 bps to 3038.25% in 2026.
- Business Quant data shows IRD's EBITDA Margin at 3038.25% in Q1 2026, 427.5% in Q4 2025, and 566.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -3,038.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,038.25% |
| Dec 31, 2025 | -427.50% |
| Sep 30, 2025 | -566.87% |
| Jun 30, 2025 | -257.46% |
| Mar 31, 2025 | -187.51% |
| Dec 31, 2024 | -816.71% |
| Sep 30, 2024 | -194.62% |
| Jun 30, 2024 | -698.29% |
| Mar 31, 2024 | -415.31% |
| Dec 31, 2023 | -283.56% |
| Sep 30, 2023 | 46.59% |
| Jun 30, 2023 | -135.03% |
| Mar 31, 2023 | -331.10% |
| Dec 31, 2022 | 85.17% |
| Sep 30, 2021 | -865.03% |
| Jun 30, 2021 | -7,136.00% |
| Mar 31, 2020 | -268.52% |
| Jun 30, 2010 | -17,008.07% |